SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Enzo Biochem, Inc. (ENZ) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 36/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ENZ
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.50
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.51
Book Value / Share$0.00
Revenue / Share$0.63
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-0.05 |
$97.6M |
$-2.29M |
-2.3% |
| 2016 |
$0.97 |
$102.77M |
$45.29M |
44.1% |
| 2017 |
$-0.05 |
$107.8M |
$-2.5M |
-2.3% |
| 2018 |
$-0.22 |
$104.71M |
$-10.32M |
-9.9% |
| 2019 |
$-2.08 |
$81.17M |
$-98.78M |
-121.7% |
| 2020 |
$-0.71 |
$76.02M |
$-33.89M |
-44.6% |
| 2021 |
$0.07 |
$117.73M |
$3.43M |
2.9% |
| 2022 |
$-0.46 |
$107.07M |
$-22.58M |
-21.1% |
| 2023 |
$-1.27 |
$31.06M |
$20.29M |
65.3% |
| 2024 |
$-0.51 |
$31.91M |
$-26.08M |
-81.7% |
